RE: Final Post20 May 2023 23:41
HH, your contribution has been first class so please dont pack it in, that said I have been there and felt the same numerous times over the years. At some point it becomes obvious, there are not enough genuine active shareholders on here to drone out the trolls. Sadly however there is nowhere else people can go too for info on Hemogenyx. The Hemo website is a farce, still has CAR-T as being in vitro testing and no mention of CBR. If there was an actual website for the company with up todate info and anyone, even a student doing their PR and some sort of social media presence I would be saying we should all abandon LSE.
Sadly however there is nothing, zilch, so please dont disappear for good, but respect your decision if that is what you do.
I will repeat a previous message though, engaging with trolls and the trolls always win, I am as guilty as anyone, but your post just proves, they won. Irrespective of how much time or effort you put into disproving every little attack or lie they will just ignore and carry on, deflect or pick something else or just post general abusive crp so that the board turns toxic.
Anyway, what we need is for the company to do some bloody pr and tell the world about themselves.
Then they need to either upgrade that god awful website or take it down because its an embarrassment how old and out of date it is, I have contacted the company many times over the past few years and its always been "planning to update". Well enough is enough, they are all scientists if they cant figure out how to update a WordPress site they should take it offline and save the hosting costs.
So for those reasons HH, please dont dissapear, when the next RNS drops it will hopefully be IND approved, Hemo going clinical and the herds will arrive looking info and the trolls will STFU. I hope you return when that happens and add your voice to the expectant rampers who will post absolute bs not actually knowing FA or caring just looking to pump for x00%. Your voice is respected and will be most welcome.